Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Aligos Therapeutics Inc (NQ: ALGS )

1.000 +0.050 (+5.25%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 30, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 43,619
Open 1.000
Bid (Size) 0.9000 (1)
Ask (Size) 1.240 (5)
Prev. Close 0.9501
Today's Range 0.9363 - 1.000
52wk Range 0.8600 - 15.58
Shares Outstanding 42,815,593
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Aligos Therapeutics Presents Clinical Data for its NASH Program and Nonclinical Data for its Chronic Hepatitis B Portfolio at AASLD’s The Liver Meeting® 2022
From Aligos Therapeutics
Via Globe NewsWire
Aligos Therapeutics Presents Clinical Data for its Capsid Assembly Modulator, ALG-000184, at AASLD’s The Liver Meeting® 2022
Reductions in hepatitis B surface antigen levels observed in a subset of subjects with chronic hepatitis B enrolled in Phase 1 study ALG-000184-201 
From Aligos Therapeutics
Via Globe NewsWire

Performance

YTD
-91.80%
-91.80%
1 Month
-4.76%
-4.76%
3 Month
-20.00%
-20.00%
6 Month
-18.03%
-18.03%
1 Year
-93.47%
-93.47%

More News

Read More
SVB Leerink Maintains Market Perform Rating for Aligos Therapeutics: Here's What You Need To Know
Via Benzinga
Aligos Co-Founders File Complaint Against Johnson & Johnson Alleging Fraud
Via Benzinga
Where Aligos Therapeutics Stands With Analysts
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
Via Benzinga
Aligos Pulls Plug On Early-Stage Chronic Hepatitis B Treatment Candidate
Via Benzinga
Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2022 Financial Results
From Aligos Therapeutics
Via Globe NewsWire
Aligos Therapeutics to Present Nonclinical and Clinical Data for its Chronic Hepatitis B and NASH Portfolio at AASLD’s The Liver Meeting® 2022
From Aligos Therapeutics
Via Globe NewsWire
Aligos Therapeutics to Announce Third Quarter Results November 2, 2022
From Aligos Therapeutics
Via Globe NewsWire
Aligos Therapeutics to Present Data on pan-Coronavirus Protease Inhibitors for the Treatment of COVID-19 at Cambridge Healthtech Institute’s 20th Annual Discovery on Target Conference, to be Held October 17-20, 2022 in Boston, MA
From Aligos Therapeutics
Via Globe NewsWire
Aligos Therapeutics Initiates Dosing In Healthy Volunteers With siRNA Drug Candidate ALG-125755
From Aligos Therapeutics
Via Globe NewsWire
Aligos Therapeutics Files Response to Janssen Biopharma Lawsuit and Lodges Counterclaims Alleging Unfair Competition and Promissory Fraud
From Aligos Therapeutics
Via Globe NewsWire
Aligos Therapeutics's Return On Capital Employed Overview
Via Benzinga
Aligos Therapeutics Earnings Preview
Via Benzinga
Aligos Therapeutics to Announce Second Quarter 2022 Results August 4, 2022
From Aligos Therapeutics
Via Globe NewsWire
Aligos Shares Fall Following Commencement Of Initial-Stage Chronic Hepatitis B Study
Via Benzinga
Aligos Therapeutics's Return On Capital Employed Insights
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 5, 2022
Via Benzinga
Preview: Aligos Therapeutics's Earnings
Via Benzinga
NASDAQ: ALGS Investor Notice: Investigation over Potential Wrongdoing at Aligos Therapeutics, Inc.
Via SBWire
Benzinga's Top Ratings Upgrades, Downgrades For March 23, 2022
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
Via Benzinga
63 Biggest Movers From Yesterday
Via Benzinga
10 Biggest Price Target Changes For Wednesday
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.